Is It Time for a New Approach to Treating Cushing’s Syndrome?
David A. Katz, PhD, CSO of Sparrow Pharmaceuticals, launched the company to specifically target the therapies bigger companies were ignoring. He talks to Endocrine News about these new therapies and how they could possibly change the way people with Cushing’s syndrome, autonomous cortisol syndrome, and other disorders are treated. For many endocrine researchers, their career...